We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Registration & abstract portal now open for PVRI 2026
Registration and abstract submissions are open for PVRI 2026, taking place 28 January – 1 February in Dublin, Ireland. With the theme Celebrating 20 Years of Progress & Innovation to mark our 20th anniversary year, we invite you to join global leaders in pulmonary hypertension for cutting-edge research, lively discussion, and impactful networking.
Meet the new faces guiding PVRI’s Innovative Drug Discovery Initiative - Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio) join Sandeep Sahay and Luke Howard in the IDDI Leadership Team.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Registration and abstract submissions are now open for PVRI 2026, taking place 28 January – 1 February in Dublin. With the theme ‘Celebrating 20 Years of Progress & Innovation’, join global leaders in pulmonary vascular science for cutting-edge research, lively discussion, and impactful networking.
Join an esteemed panel of international leaders as they share their approaches to bridging pediatric patients to lung transplantation. This dynamic session will feature focused presentations from each speaker, followed by interactive panel discussions of two real-world clinical cases.
'Pulmonary hypertension in the shadow of infections: challenges in Indian practice' is part of the Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
To kick off the relaunch of the Women’s Health Task Force, co-chairs Jessica Badlam, University of Vermont Medical Center, and Meghan Cirulis, Intermountain Health Intermountain Medical Center, have put together a dedicated webinar exploring the intersection of women’s health and pulmonary vascular disease. The session will feature expert scientific presentations and open discussion, with time set aside to introduce the Task Force’s renewed objectives and future goals.
Part of the 'Hypoxia in pulmonary vascular research – altitude and beyond' webinar series by the High Altitude Task Force, who raise awareness and understanding of PH linked to high altitude and organise scientific conferences in regions affected by high altitudes.
Portopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear.
Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) require a multifaceted, guideline-directed management approach. This includes active patient participation in partnership with their healthcare team to minimize disease impact and improve survival.
We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.
Your feedback is needed on our work groups and subject areas...We’re reviewing some of our IDDI Workstream activity, and we need you to help us shape the future agenda.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
